Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III booster study of Hexyon/DTaP-IPV-HB-Hib versus Infanrix hexa in infants and toddlers
2012-001042-18Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Hexyon, pertussis filamentous haemagglutinin, pneumococcal 13-valent conjugate vaccine in diphtheria, Tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b invasive infection (Hib), sponsored by Sanofi. Started Jun 2014; status: completed.
02
Drugs
Hexyonpertussis filamentous haemagglutininpneumococcal 13-valent conjugate vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b invasive infection (Hib)
Beyond the preview
Go deeper on 2012-001042-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001042-18.